Recent Stories
Isis Pharmaceuticals Reports Q4 Results
Isis Pharmaceuticals Inc. reported a significantly improved fourth quarter net income of $31 million, up from a net loss of $24.3 million in the same quarter last year.
Formula Is New CEO, New Home, Old Drug
BIOTECH: Investors See Good Bet in Heart Drug
San Diego’s abundance of intellectual capital and venture investors with deep pockets has lured yet another startup from its snow-steeped home to sunny Southern California.
